Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?

Simply Wall St.04-12 04:28

Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626889120?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-12 04:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626889120","market":"nz","top_or_hot":-1,"title":"Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-12 04:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","article_id":"2626889120","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626889120","pubTimestamp":1775939339,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint.\nThis move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK4006":"钢铁","LABU":"三倍做多标普生物-Direxion","MSB":"美莎比信托","BK4588":"碎股","BK4585":"ETF&股票定投概念","MSB.AU":"MESOBLAST LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"FDA批准的Ryoncil杜兴试验是否改变了Mesoblast(ASX：MSB)的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB":1.5,"LABU":1.5,"MSB.AU":1.5},"content_text":"Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint. This move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project Muscular Dystrophy to support trial awareness and recruitment. We’ll now examine how FDA clearance for a registrational Duchenne muscular dystrophy trial might influence Mesoblast’s long-term cell therapy investment narrative. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementMesoblast Investment Narrative RecapTo own Mesoblast, you need to believe that Ryoncil’s first approved niche in pediatric steroid refractory GvHD can widen into multiple inflammatory and cardiovascular indications, eventually supporting a move toward profitability from today’s loss making base. The new IND clearance in Duchenne muscular dystrophy adds another potential label, but the key near term catalyst still sits in late stage programs such as chronic low back pain and adult GvHD, while the biggest risk remains sustained cash burn if trial timelines slip or uptake underwhelms. The recent update that Ryoncil generated US$30.3 million in quarterly net sales, with revenue since launch nearing US$100 million, is highly relevant here, as it provides funding capacity to pursue this DMD registrational trial alongside other pivotal studies. That growing, though still modest, revenue base helps support Mesoblast’s multi indication ambitions but does not remove the execution risk around large trials, regulatory decisions and future reimbursement outcomes. Yet investors should also recognise that if Ryoncil sales plateau or reimbursement tightens, the company’s ability to fund all these late stage programs without fresh capital could... Read the full narrative on Mesoblast (it's free!)Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.Uncover how Mesoblast's forecasts yield a A$3.83 fair value, a 81% upside to its current price.Exploring Other PerspectivesASX:MSB 1-Year Stock Price Chart Some analysts were far more optimistic, assuming revenue could reach about US$1.1 billion and earnings around US$585.1 million by 2028, while this DMD trial highlights how differently you and those bullish views might assess the balance between rapid label expansion and the real risk that heavy, multi program spending does not pay off as expected.Explore 12 other fair value estimates on Mesoblast - why the stock might be worth less than half the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Mesoblast research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Mesoblast research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.Interested In Other Possibilities?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:AI is about to change healthcare. These 10 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Uncover the next big thing with 58 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626889120","isCrawlerRequest":true}